Antigen selection reflected in the subclonal architecture of the B‐cell receptor immunoglobulin gene repertoire in splenic marginal zone lymphoma
Laura Zaragoza‐Infante,
Andreas Agathangelidis,
Anastasia Iatrou,
Valentin Junet,
Nikos Pechlivanis,
Maria Karypidou,
Triantafyllia Koletsa,
Giorgos Karakatsoulis,
Alessio Bruscaggin,
Zadie Davis,
Valeria Spina,
Aurelie Verney,
Eleftheria Polychronidou,
Fotis Psomopoulos,
David Oscier,
Alexandra Traverse‐Glehen,
Maria Papaioannou,
Paolo Ghia,
Davide Rossi,
Anastasia Chatzidimitriou,
Kostas Stamatopoulos
Affiliations
Laura Zaragoza‐Infante
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Andreas Agathangelidis
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Anastasia Iatrou
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Valentin Junet
Anaxomics Biotech SL Barcelona Spain
Nikos Pechlivanis
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Maria Karypidou
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Triantafyllia Koletsa
Department of Pathology, Faculty of Medicine Aristotle University of Thessaloniki Thessaloniki Greece
Giorgos Karakatsoulis
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Alessio Bruscaggin
Institute of Oncology Research, Laboratory of Experimental Hematology Bellinzona Switzerland
Zadie Davis
Department of Haematology Royal Bournemouth Hospital Bournemouth United Kingdom
Valeria Spina
Institute of Oncology Research, Laboratory of Experimental Hematology Bellinzona Switzerland
Aurelie Verney
Centre International de Recherche en Infectiologie, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, Ecole Normale Supérieure de Lyon Université de Lyon Lyon France
Eleftheria Polychronidou
Department of Biology National and Kapodistrian University of Athens Athens Greece
Fotis Psomopoulos
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
David Oscier
Department of Haematology Royal Bournemouth Hospital Bournemouth United Kingdom
Alexandra Traverse‐Glehen
Centre International de Recherche en Infectiologie, INSERM U1111, Université Claude Bernard Lyon 1, CNRS UMR5308, Ecole Normale Supérieure de Lyon Université de Lyon Lyon France
Maria Papaioannou
First Department of Medicine Aristotle University of Thessaloniki Thessaloniki Greece
Paolo Ghia
Division of Experimental Oncology Università Vita‐Salute San Raffaele, IRCCS Ospedale San Raffaele Milan Italy
Davide Rossi
Institute of Oncology Research, Laboratory of Experimental Hematology Bellinzona Switzerland
Anastasia Chatzidimitriou
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Kostas Stamatopoulos
Institute of Applied Biosciences Centre for Research and Technology Hellas Thessaloniki Greece
Abstract Almost one‐third of all splenic marginal zone lymphoma (SMZL) cases express B‐cell receptor immunoglobulin (BcR IG) encoded by the IGHV1‐2*04 gene, implicating antigen selection in disease ontogeny. Evidence supporting this notion mostly derives from low‐throughput sequencing approaches, which have limitations in capturing the full complexity of the BcR IG gene repertoire. This hinders the comprehensive assessment of the subclonal architecture of SMZL as shaped by antigen selection. To address this, we conducted a high‐throughput immunogenetic investigation of SMZL aimed at the comprehensive characterization of the somatic hypermutation (SHM) and intraclonal diversification within the IG genes. We identified significant differences in the SHM and ID profiles between cases expressing the IGHV1‐2*04 gene and those expressing other IGHV genes. Specifically, IGHV1‐2*04 cases displayed (i) targeted SHM resulting in recurrent replacement SHMs, and (ii) significantly more pronounced intraclonal diversification, reflecting ongoing antigen selection. Overall, our findings suggest that SMZL cases expressing the IGHV1‐2*04 gene have a distinct immunogenetic signature shaped by microenvironmental pressure on the clonotypic BcR IG, corroborating the idea that this group may represent a distinct molecular variant of SMZL.